Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glyceryl eicosapentaenoate (Mimetica)
- Development stage
- Unknown
- Lead developer
- SCF Pharma
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Glyceryl eicosapentaenoate (GEPA) is a synthetic monoacylglycerol derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). Developed by Mimetica (a subsidiary of Nippon Zoki Pharmaceutical), GEPA is a topical small molecule designed to treat inflammatory skin conditions, primarily acne vulgaris. It acts as a stable delivery vehicle for EPA, which is released upon application to the skin. EPA exerts its therapeutic effects by inhibiting the production of pro-inflammatory cytokines such as interleukin-8 (IL-8) and leukotriene B4 (LTB4), and by demonstrating antimicrobial activity against *Cutibacterium acnes*. The specific combination of a serum and a cream formulation (such as Cream B) has been evaluated in clinical trials to optimize the delivery of the active ingredient to the pilosebaceous unit and improve clinical outcomes in patients with moderate-to-severe acne.
- Other names
- GEPA2-eicosapentaenoylglycerolmono-eicosapentaenoyl glycerolglyceryl eicosapentaenoate serumglyceryl eicosapentaenoate cream B
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)FFAR4 (Free fatty acid receptor 4)
Beyond the preview
Go deeper on glyceryl eicosapentaenoate (Mimetica).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glyceryl eicosapentaenoate (Mimetica).